Business context and reporting period
Filing identity: The supplied filing is Calyxt, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 3, 2022. This does not match the request metadata identifying Cibus, Inc.; the summary below reflects the filing text provided, not a Cibus filing. It is an annual report, not a standalone fourth-quarter report.
Calyxt is an early-stage plant-based synthetic biology company. In October 2021, it shifted its primary strategy toward developing plant-based compounds using its PlantSpring platform and BioFactory system, targeting cosmeceutical, nutraceutical and pharmaceutical customers. Its 2021 revenue, however, came almost entirely from its legacy soybean business, which it completed winding down late in the year.
Financial results and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $26.0 million | $23.9 million |
| Gross profit (loss) | $(2.6) million; approximately -10% margin | $(11.3) million; approximately -47% margin |
| Operating expenses | $26.8 million | $32.6 million |
| Operating loss | $(29.3) million | $(43.8) million |
| Net loss | $(29.2) million | $(44.8) million |
| Operating cash flow | $(18.8) million | $(43.7) million |
| Adjusted EBITDA loss (non-GAAP) | $(24.9) million | $(31.6) million |
Revenue rose 9%, primarily from greater sales volume and higher commodity prices on soybean grain. The company reported no soybean grain, oil or meal inventory or accounts receivable at year-end after completing the product-line wind-down. Although gross loss improved, gross profit remained negative. Operating cash use fell substantially, in part because the wind-down released working capital; management expected operating cash use to rise in 2022 as that benefit ended and investment in BioFactory and AIML increased.
At December 31, 2021, cash and cash equivalents were $13.8 million and restricted cash was $0.6 million, for total cash, cash equivalents and restricted cash of $14.4 million. Current liabilities were $4.9 million. Financing lease obligations totaled $17.9 million ($0.4 million current and $17.5 million non-current); there was no long-term debt after forgiveness of the PPP loan. Total liabilities were $23.1 million. The filing lists $7.7 million of lease payments due within five years and $1.8 million of remaining severance obligations, including $1.1 million due in 2022.
Material changes versus the prior year
- Net loss improved by $15.6 million, reflecting improved gross results, lower SG&A and a $1.5 million gain from PPP loan forgiveness. SG&A fell 25% to $15.4 million; R&D increased 2% to $11.3 million.
- Gross loss narrowed by $8.7 million. Management attributed the change to selling grain rather than soybean oil and meal, commodity-derivative effects, and lower inventory valuation adjustments. Adjusted gross loss, a non-GAAP measure, was $5.7 million versus $7.2 million.
- Operating cash use improved by $24.9 million, with a $13.2 million favorable change in operating assets and liabilities associated with the soybean business wind-down.
- Cash, cash equivalents and restricted cash declined from $18.3 million to $14.4 million. The company used short-term investments to fund operations and held none at year-end, compared with $11.7 million in 2020.
- The pilot-scale BioFactory became operational in December 2021. The first pilot bioreactor is scalable up to 200 liters.
Outlook, risks and unusual items
Management estimated that cash, including the $10.0 million net proceeds from a February 2022 stock-and-warrant offering, would fund planned operations into late 2022. Management concluded that substantial doubt existed about the company’s ability to continue as a going concern because additional capital would be needed to support its business plan for at least 12 months from the filing date. The auditor’s report also highlighted this going-concern uncertainty; the financial statements were prepared on a going-concern basis.
The February 2022 offering comprised 3.88 million common shares, pre-funded warrants for up to 3.88 million shares and common warrants for up to 7.76 million shares. The filing warns that further financing may not be available on acceptable terms and could dilute shareholders or add fixed obligations. ATM sales were also subject to SEC “baby shelf” limits because of the company’s public float.
Management’s stated target was to have two to four plant-based chemistries in development by the end of 2022. It estimated about 12 months for its Design-Engineer-Verify process and roughly 24 additional months from pilot development to commercialization, with longer timelines possible for regulated applications. These are plans and estimates, not assured outcomes. Management expected 2022 capital spending on BioFactory and AIML capabilities to exceed 2021 levels.
Key execution risks include whether the relatively unproven BioFactory can scale economically, whether customers will sign and fund development programs and ultimately buy products, reliance on third-party infrastructure partners for commercial-scale production, competition, regulatory acceptance, intellectual-property challenges and the ability to raise capital. The filing reported no material pending legal proceedings and no material COVID-19 impact on 2021 operations, while cautioning that future effects remained uncertain.
Important facts for investors to verify
- Confirm the issuer and filing: the provided text is Calyxt, Inc.’s 2021 Form 10-K, not a Cibus, Inc. filing.
- Review the going-concern disclosure and the company’s funding needs beyond the stated late-2022 cash runway; check subsequent financing, cash use and any cost reductions.
- Track customer agreements, development funding, pipeline progress and whether the target of two to four compounds in development by end-2022 was achieved.
- Assess BioFactory pilot results, commercial-scale yields and costs, infrastructure-partner arrangements, and any timing or capital requirements not quantified in this filing.
- Distinguish legacy soybean revenue and non-GAAP adjusted measures from recurring revenue and GAAP results; verify customer demand and product economics as the business transitions.
- Consider potential dilution from the February 2022 offering, warrants, ATM facility and equity compensation, as well as Cellectis’s 61.8% ownership at year-end 2021.